Eoin Flanagan
Neurology · Rochester, MNNPI 1649435058
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by UCB GmbH at 58.3% of the total. 2025 is the largest year on record at $33,555, 4.6 times the $7,282 reported in 2021. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $1767.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB GmbH$32K
- AstraZeneca$7K
- F. Hoffmann-la Roche AG$6K
- Amgen$5K
- UCB SA$3K
- Genentech USA, Inc.$2K
Across 33 payments — averaging $49,145 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$927K
- Genentech, Inc.$521K
- AstraZeneca$173K
What the payments were for
- Consulting fees$17,61632%
- Speaking & faculty fees$4,7629%
- Travel & lodging$31,93658%
- Food & beverage$4811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB GmbH | 8 | $31,936 |
| AstraZeneca | 4 | $7,217 |
| F. Hoffmann-la Roche AG | 9 | $6,254 |
| Amgen(2 entities) | 7 | $5,033 |
| UCB SA | 1 | $2,750 |
| Genentech USA, Inc. | 2 | $1,606 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,796 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 12 | $113,297 |
| Prednisone | 32 | $802 |
| Baclofen | 16 | $372 |
| Pregabalin | 14 | $319 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Wolfgang SingerRochester$128K
- Ronald PetersenRochester$126K
- Partha GhoshRochester$121K
- Keith CoffmanRochester$24K
- Igal MirmanRochester$18K
- P James DyckRochester$17K
- Suresh KotagalRochester$16K
- Chia-Chun ChiangRochester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.